Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Chinese Herbal Asthma Treatment Comparable To Prednisone – Study

This article was originally published in The Tan Sheet

Executive Summary

A Chinese asthma herbal medicine intervention (ASHMI) was found to be an effective treatment for allergic asthma, a study published in the September Journal of Allergy & Clinical Immunology states

You may also be interested in...



New NCCAM centers

The National Center for Complementary & Alternative Medicine expands its research centers program with the addition of three centers for excellence and two international centers, NCCAM announces Oct. 14. Newly established Center for Arthritis & Traditional Chinese Medicine at the University of Maryland will receive $1.2 mil. to investigate acupuncture and herbs for arthritis treatment, while the Center for Chinese Herbal Therapy at Mount Sinai School of Medicine in New York is granted $1.4 mil. to evaluate the three-herb Chinese formula ASHMI as a therapy for allergies asthma. The use of traditional Chinese herbal formulas for conditions such as irritable bowl syndrome and cancer, will be explored at the international centers, according to NCCAM. The safety and efficacy of traditional African plant-based therapies for HIV/AIDS and associated conditions will also be explored...

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Avoiding GMP “Showstoppers” Keeps Manufacturers Off FDA’s “Radar”

Compliance consultants warn that certain dietary supplement good manufacturing practices violations are inspection "showstoppers" and will draw agency enforcement

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS098750

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel